COVID-19: Bharat Biotech ready for Covaxin's clinical trial in US

The full data from studies on Covaxin's neutralisation of variants are already published.

New Delhi: Bharat Biotech said in a statement that it will be carrying out clinical trials in the United States to support the marketing application for Covaxin. The US Food and Drug Administration (USFDA) had decided not to give Emergency Use Authorisation (EUA) to Bharat Biotech’s Covaxin.  The regulator also recommended Ocugen, the US partner for Bharat Biotech’s COVID-19 vaccine, to pursue Biologics License Applications (BLA) path for Covaxin.